on IKONISYS (EPA:ALIKO)
Ikonisys SA announces promising annual results for 2025
Ikonisys SA has published its financial results for 2025, marked by a 52.6% increase in operating revenue, reaching €1.64 million. This growth is attributed to the integration of Hospitalex and the rollout of Aliko Scientific's offering. EBITDA also showed a 32.9% improvement, despite a loss of €1.14 million.
The group has focused on developing its integrated oncology diagnostic platform, marked by obtaining a US patent for ACTA technology and launching Urine24. An exclusive distribution agreement with Menarini Diagnostics in Italy complements these advances.
Despite a net loss of 4.2 million euros, Ikonisys strengthened its financial operations and cash position to 1.03 million euros as of December 31, 2025.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all IKONISYS news